Anti-cocaine vaccine development

References

• Ruetsch YA, Boni T, Borgeat A. From cocaine to ropivacaine: the history of local anesthetic drugs. Curr. Top. Med. Chem.1(3), 175–182 (2001).
   PubMedGoogle Scholar
• Wilson R. Drug Abuse Prevention: a School and Community Partnership. Jones & Bartlett, Sudbury, MA, USA (2010).
   Google Scholar
• Watkins D, Ashby R. Gang Investigations: a Street Cop’s Guide. Jones & Bartlett, Sudbury, MA, USA (2007).
   Google Scholar
• Preti A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol.12(2), 133–151 (2007).
   PubMed Web of Science ®Google Scholar
• White JM, Lopatko OV. Opioid maintenance: a comparative review of pharmacological strategies. Expert Opin. Pharmacother.8(1), 1–11 (2007).
   PubMed Web of Science ®Google Scholar
• Berzofsky JA, Berkower IJ (Eds). Immunogenicity and Antigen Structure. Raven Press, NY, USA (1989).
   Google Scholar
• Eisen HN, Siskind GW. Variations in affinities of antibodies during the immune response. Biochemistry3, 996–1008 (1964).
   PubMed Web of Science ®Google Scholar
• deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA278(22), 1895–1906 (1997).
   PubMed Web of Science ®Google Scholar
• Falugi F, Petracca R, Mariani M et al. Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur. J. Immunol.31(12), 3816–3824 (2001).
   PubMed Web of Science ®Google Scholar
• Berkowitz B, Spector S. Evidence for active immunity to morphine in mice. Science178(67), 1290–1292 (1972).
   PubMed Web of Science ®Google Scholar
• Spector S, Berkowitz B, Flynn EJ, Peskar B. Antibodies to morphine, barbiturates, and serotonin. Pharmacol. Rev.25(2), 281–291 (1973).
   PubMed Web of Science ®Google Scholar
• Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: methadone. J. Addict. Dis.29(2), 200–216 (2010).
   PubMed Web of Science ®Google Scholar
• Bagasra O, Forman LJ, Howeedy A, Whittle P. A potential vaccine for cocaine abuse prophylaxis. Immunopharmacology23(3), 173–179 (1992).
   PubMed Web of Science ®Google Scholar
• Isomura S, Wirsching P, Janda KD. An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J. Org. Chem.66(12), 4115–4121 (2001).
   PubMed Web of Science ®Google Scholar
• de Villiers SH, Lindblom N, Kalayanov G et al. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine28(10), 2161–2168 (2010).
   PubMed Web of Science ®Google Scholar
• Cerny EH, Cerny T. Vaccines against nicotine. Hum. Vaccin.5(4), 200–205 (2009).
   PubMed Web of Science ®Google Scholar
• Duryee MJ, Bevins RA, Reichel CM et al. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine27(22), 2981–2988 (2009).
   PubMed Web of Science ®Google Scholar
• Gentry WB, Ruedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Hum. Vaccin.5(4), 206–213 (2009).
   PubMed Web of Science ®Google Scholar
• Li P, Zhao K, Deng S, Landry DW. Nonenzymatic hydrolysis of cocaine via intramolecular acid catalysis. Helvetica Chimica Acta82, 85–89 (1999).
   Web of Science ®Google Scholar
• Warner A, Norman AB. Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification. Ther. Drug Monit.22(3), 266–270 (2000).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Mattes CE, Singh A et al. Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol. Appl. Pharmacol.145(2), 363–371 (1997).
   PubMed Web of Science ®Google Scholar
• Chandrakumar NS, Carron CP, Meyer DM et al. Phenylphosphonate monoester analogs of cocaine. Potential haptens for the generation of catalytic antibodies. Bioorg. Med. Chem. Lett.3(2), 309–312 (1993).
   Web of Science ®Google Scholar
• Baird TJ, Deng SX, Landry DW, Winger G, Woods JH. Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J. Pharmacol. Exp. Ther.295(3), 1127–1134 (2000).
   PubMed Web of Science ®Google Scholar
• Briscoe RJ, Jeanville PM, Cabrera C et al. A catalytic antibody against cocaine attenuates cocaine’s cardiovascular effects in mice: a dose and time course analysis. Int. Immunopharmacol.1(6), 1189–1198 (2001).
   PubMed Web of Science ®Google Scholar
• Landry DW, Zhao K, Yang GX, Glickman M, Georgiadis TM. Antibody-catalyzed degradation of cocaine. Science259(5103), 1899–1901 (1993).
   PubMed Web of Science ®Google Scholar
• Mets B, Winger G, Cabrera C et al. A catalytic antibody against cocaine prevents cocaine’s reinforcing and toxic effects in rats. Proc. Natl Acad. Sci. USA95(17), 10176–10181 (1998).
   PubMed Web of Science ®Google Scholar
• Basmadjian GP, Singh S, Sastrodjojo B et al. Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to diphtheria toxoid. Chem. Pharm. Bull (Tokyo)43(11), 1902–1911 (1995).
   PubMed Web of Science ®Google Scholar
• Berkman CE, Underiner GE, Cashman JR. Synthesis of an immunogenic template for the generation of catalytic antibodies for (-)-cocaine hydrolysis. J. Org. Chem.61, 5686–5689 (1996).
   Web of Science ®Google Scholar
• Deng SX, de Prada P, Landry DW. Anticocaine catalytic antibodies. J. Immunol. Methods269(1–2), 299–310 (2002).
   PubMed Web of Science ®Google Scholar
• Cashman JR, Berkman CE, Underiner GE. Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. J. Pharmacol. Exp. Ther.293(3), 952–961 (2000).
   PubMed Web of Science ®Google Scholar
• Matsushita M, Hoffman TZ, Ashley JA et al. Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg. Med. Chem. Lett.11(2), 87–90 (2001).
   PubMed Web of Science ®Google Scholar
• McKenzie KM, Mee JM, Rogers CJ et al. Identification and characterization of single chain anti-cocaine catalytic antibodies. J. Mol. Biol.365(3), 722–731 (2007).
   PubMed Web of Science ®Google Scholar
• Gallacher G. A potential vaccine for cocaine abuse prophylaxis? Immunopharmacology27(1), 79–84 (1994).
   PubMed Web of Science ®Google Scholar
• Carrera MR, Ashley JA, Parsons LH et al. Suppression of psychoactive effects of cocaine by active immunization. Nature378(6558), 727–730 (1995).
   PubMed Web of Science ®Google Scholar
• Carrera MR, Ashley JA, Zhou B et al. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl Acad. Sci. USA97(11), 6202–6206 (2000).
   PubMed Web of Science ®Google Scholar
• Sakurai M, Wirsching P, Janda KD. Design and synthesis of a cocaine-diamide hapten for vaccine development. Tetrahedron Lett.37, 5479–5482 (1996).
   Web of Science ®Google Scholar
• Carrera MR, Ashley JA, Wirsching P, Koob GF, Janda KD. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl Acad. Sci. USA98(4), 1988–1992 (2001).
   PubMed Web of Science ®Google Scholar
• Fox BS, Kantak KM, Edwards MA et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med.2(10), 1129–1132 (1996).
   PubMed Web of Science ®Google Scholar
• Ettinger RH, Ettinger WF, Harless WE. Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol. Biochem. Behav.58(1), 215–220 (1997).
   PubMed Web of Science ®Google Scholar
• Johnson MW, Ettinger RH. Active cocaine immunization attenuates the discriminative properties of cocaine. Exp. Clin. Psychopharmacol.8(2), 163–167 (2000).
   PubMed Web of Science ®Google Scholar
• Schabacker DS, Kirschbaum KS, Segre M. Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2β anti-idiotypic antibodies. Immunology100(1), 48–56 (2000).
   PubMed Web of Science ®Google Scholar
• Kantak KM, Collins SL, Bond J, Fox BS. Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berl.)153(3), 334–340 (2001).
   PubMed Web of Science ®Google Scholar
• Kantak KM, Collins SL, Lipman EG et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl.)148(3), 251–262 (2000).
   PubMed Web of Science ®Google Scholar
• Koetzner L, Deng S, Sumpter TL et al. Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. J. Pharmacol. Exp. Ther.296(3), 789–796 (2001).
   PubMed Web of Science ®Google Scholar
• Hrafnkelsdottir K, Valgeirsson J, Gizurarson S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol. Pharm. Bull.28(6), 1038–1042 (2005).
   PubMed Web of Science ®Google Scholar
• Kosten TR, Biegel D. Therapeutic vaccines for substance dependence. Expert Rev. Vaccines1(3), 363–371 (2002).
   PubMedGoogle Scholar
• Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry58(2), 158–164 (2005).
   PubMed Web of Science ®Google Scholar
• Martell BA, Orson FM, Poling J et al. Cocaine vaccine for the treatment of cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Arch. Gen. Psych.66, 1116–1123 (2009).
   PubMed Web of Science ®Google Scholar
• Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J. Anal. Toxicol.26(7), 382–392 (2002).
   PubMed Web of Science ®Google Scholar
• Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry67(1), 59–65 (2010).
   PubMed Web of Science ®Google Scholar
• Deliyannis G, Kedzierska K, Lau YF et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur. J. Immunol.36(3), 770–778 (2006).
   PubMed Web of Science ®Google Scholar
• Iyer S, HogenEsch H, Hem SL. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine21(11–12), 1219–1223 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Narasimhan D, Sunahara RK et al. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol. Pharmacol.70(6), 1885–1891 (2006).
   PubMed Web of Science ®Google Scholar
• Gao D, Narasimhan DL, Macdonald J et al. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol. Pharmacol.75(2), 318–323 (2009).
   PubMed Web of Science ®Google Scholar
• Wood SK, Narasimhan D, Cooper Z, Sunahara RK, Woods JH. Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug Alcohol Depend.106(2–3), 219–229 (2010).
   PubMed Web of Science ®Google Scholar
• Gao Y, Brimijoin S. Lasting reduction of cocaine action in neostriatum – a hydrolase gene therapy approach. J. Pharmacol. Exp. Ther.330(2), 449–457 (2009).
   PubMed Web of Science ®Google Scholar
• Gao Y, Orson FM, Kinsey BM, Kosten TR, Brimijoin S. The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chem. Biol. Interact187(1–3), 421–424 (2010).
   PubMed Web of Science ®Google Scholar
• Malaitsev VV, Azhipa O. The effect of epitope density on the immunogenic properties of hapten–protein conjugates. Biull. Eksp. Biol. Med.115(6), 645–646 (1993).
   PubMedGoogle Scholar
• Sunthornchart S, Linkins RW, Natephisarnwanish V et al. Prevalence of hepatitis B, tetanus, hepatitis A, human immunodeficiency virus and feasibility of vaccine delivery among injecting drug users in Bangkok, Thailand, 2003–2005. Addiction103(10), 1687–1695 (2008).
   PubMed Web of Science ®Google Scholar